Emcure Pharma, backed by the private equity firm Bain Capital and promoted by Shark Tank India fame Namita Thapar, launched its IPO on July 03 to raise a total of Rs 1,952.03 crore. 

The company closed the bidding for its IPO subscription on July 05. It received bidding almost 68 times more than the offered shares. In the retail segment, the public issue was subscribed 7.4 times. While it got the highest bidding in the QIB segment standing at 191.24 times. The NII category got bids over 49 times as of July 05.

Now, the allotment of the shares will be finalised by July 08. The investors who applied can check the allotment status in five simple steps: 

Step 1

Go to the website of the registrar handling the issue. In Emcure Pharma’s IPO, Link Intime India is the registrar. 

Step 2

Click on the public issue section on the left side of the webpage. 

Step 3 

Enter details like the company’s name and PAN number/ application number/ client ID/ account number. 

Step 4

Hit the submit button

Step 5

A screen will pop up with the status. 

Listing Details

The listing is expected to take place on July 10 on the NSE and BSE mainboard platforms as per the tentative schedule. 

IPO Details

Emcure Pharma had a combination of a fresh issue of 7.9 million shares aggregating to Rs 800 and an offer for sale of 11.4 million shares amounting to Rs 1,152.03 crores.

Price Band


Emcure Pharma kept the price band in a range of Rs 960 to Rs 1008 per equity share. 

Minimum Investment

A retail buyer had to buy for at least one lot containing 14 shares aggregating to Rs 14,112. While for NIIs and QIBs the minimum investment required is different than that of retailers. An application from a small NII should have applied for at least 210 shares and big NII 994 shares. 

Employee Reservation

The issue had kept aside 108,900 shares for the employees, which were available to them at a discount of Rs 90 per equity share to the issue price. 

BRLMs 

Kotak Mahindra Capital Company, Axis Capital, J.P. Morgan India, and Jefferies India were working as the book-running lead managers for the issue of Emcure Pharma.